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A B S T R A C T
Carbon monoxide (CO)-releasing molecules (CORMs), mostly metal carbonyl compounds, are extensively used as
experimental tools to deliver CO, a biological ‘gasotransmitter’, in mammalian systems. CORMs are also explored
as potential novel antimicrobial drugs, eﬀectively and rapidly killing bacteria in vitro and in animal models, but
are reportedly benign towards mammalian cells. Ru-carbonyl CORMs, exempliﬁed by CORM-3 (Ru(CO)3Cl
(glycinate)), exhibit the most potent antimicrobial eﬀects against Escherichia coli. We demonstrate that CORM-3
releases little CO in buﬀers and cell culture media and that the active antimicrobial agent is Ru(II), which binds
tightly to thiols. Thus, thiols and amino acids in complex growth media – such as histidine, methionine and
oxidised glutathione, but most pertinently cysteine and reduced glutathione (GSH) – protect both bacterial and
mammalian cells against CORM-3 by binding and sequestering Ru(II). No other amino acids exert signiﬁcant
protective eﬀects. NMR reveals that CORM-3 binds cysteine and GSH in a 1:1 stoichiometry with dissociation
constants, Kd, of about 5 μM, while histidine, GSSG and methionine are bound less tightly, with Kd values
ranging between 800 and 9000 μM. There is a direct positive correlation between protection and amino acid
aﬃnity for CORM-3. Intracellular targets of CORM-3 in both bacterial and mammalian cells are therefore ex-
pected to include GSH, free Cys, His and Met residues and any molecules that contain these surface-exposed
amino acids. These results necessitate a major reappraisal of the biological eﬀects of CORM-3 and related
CORMs.
1. Introduction
Over the past decade, novel transition metal-based carbon mon-
oxide-releasing molecules (CORMs) have been developed to deliver
physiologically relevant levels of CO experimentally or therapeutically
[1,2]. The widespread use of these compounds as CO-donors in over
300 biological studies has accelerated our understanding of CO as an
important gasotransmitter molecule in human and animal biology [3].
Increasingly, CORMs are considered as potential pro-drugs for CO de-
livery, not only in clinical and physiological applications [4,5], but also
as anticancer drugs [6] and antimicrobials [7].
One of the earliest and most widely used CORMs is the water-so-
luble CORM-3 (Ru(CO)3Cl(glycinate) Fig. 1(a). Its biological activities
are complicated by an extensive solution chemistry [8–10]: upon so-
lubilisation in water, [Ru(CO)2(CO2H)Cl(glycinate)]- isomers are gen-
erated by attack of hydroxide ions on CORM-3 – the initial step of
Water-Gas-Shift-Reaction (WGSR) chemistry. Various biologically ac-
tive metal-carbonyl complexes are formed, which may exhibit diﬀerent
reactivities and extents of CO-release [10]. CORM-3 has shown promise
as an antimicrobial agent in infection models. CORM-3 not only in-
hibited growth and respiration of Pseudomonas aeruginosa in vitro, but
also decreased bacterial counts in the spleen of both immunocompetent
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and immune-suppressed mice [11]. CORM-3 is toxic against laboratory
strains and clinical isolates of Escherichia coli, Campylobacter jejuni,
Lactobacillus lactis, Staphylococcus aureus and Salmonella enterica serovar
Typhimurium [10]. Injection of the related CORM-2 (Ru2Cl4(CO)6) into
mice increased phagocytosis of bacteria and rescued heme oxygenase-
deﬁcient mice from sepsis-induced lethality [12]. Since CORM-3 accu-
mulates in bacterial cells (assessed by Ru uptake) and inhibits re-
spiration [13,14], an early assumption was that its activity was due to
intracellular release of CO, which binds to terminal oxidases, thereby
inhibiting respiration. There is ample spectroscopic evidence that the
released CO binds ferrous hemes in strongly reducing conditions in the
absence of oxygen, but any direct link between respiratory inhibition
and bactericidal activity is unproven. Thus, CORM-3 is considered
primarily a CO-carrier or ‘Trojan Horse’ [15–17], delivering a toxic
cargo of CO, with the residual Ru ion(s) contributing only a minor role
in antimicrobial activity. Other investigators have suggested that anti-
microbial activity is due in part to generation of reactive oxygen spe-
cies, perhaps following respiratory inhibition [18,19]. An important
unresolved issue in the potential application of CORMs as antimicrobial
drugs is why CORM-3 possesses potent antimicrobial activity, yet is
reportedly non-toxic to mammalian cells, ex vivo and whole-animal
models, where it exerts therapeutic (including vasodilatory, anti-in-
ﬂammatory and cardioprotective) eﬀects [20,21].
A radically diﬀerent explanation for the toxic biological activities of
these Ru-carbonyl CORMs is that, rather than acting via release of CO,
they are sources of Ru(II), which reacts with cellular targets. Indeed,
over 200 publications report the antimicrobial activities of various Ru-
based compounds that are not CORMs; in some, the Ru ions play a
direct functional role, directly coordinating to biological targets [10].
Here, we investigate this hypothesis, using a range of biological and
biophysical measures, and conclude that CORM-3 releases very little CO
under the conditions generally adopted in biological experiments and
that the cellular toxicity of CORM-3 is mainly due to the reactions of Ru
(II) with thiols and amino acids. These ﬁndings have far-reaching im-
plications for the toxicity and pharmacological development of these
agents against both bacterial and mammalian cells, and the future use
of CORM-3 and related compounds as inert ‘CO-carrier’ vehicles in
biological research.
2. Materials and methods
2.1. CORM-3, tricarbonylchloro (glycinato)ruthenium(II), C5H4ClNO5Ru
CORM-3 was synthesized from CORM-2 (Sigma-Aldrich), as
described previously [20]. Stock solutions were in distilled H2O (ﬁnal
concentration 1 – 100mM), shielded from light and used on the day of
preparation. Prior to biological assays, CORM-3 solutions were ﬁlter-
sterilised through a 0.22 µm ﬁlter.
2.2. CO release from CORM-3
Liberation of CO from CORM-3 was determined by gas-phase
Fourier-transform infrared spectroscopy (FTIR) or via myoglobin (Mb)
assays. For FTIR, CO detection was as described previously [22] except
that a White multiple-pass absorption cell (providing a total folded path
length of 8m) and a cooled detector (EG & G Optoelectronics J15D14
MCT) were used. CO was quantiﬁed by Lorentzian ﬁtting of 6 isolated
lines (R3, R5, R6, R8, R9 and R10) and comparison of the line integrals
with a simulated spectrum generated using absorption coeﬃcients from
the HITRAN 2012 database [23]. Measurements of CO release from
CORM-3 in various growth media (deﬁned minimal salts medium
supplemented with 20mM glucose ‘GDMM’ [24], LB (Formedium), MH-
II (Sigma-Aldrich), DMEM or RPMI (Sigma-Aldrich) or 30mM KPi
buﬀer pH 7.4 were conducted as follows. CORM-3 (100 μM) was added
to 10mL vigorously stirred, degassed, sterile media or buﬀer in a sealed
vessel connected to the FTIR absorption cell. A peristaltic pump (ﬂow
rate 7 L h−1) was used to bring the vessel headspace and the IR ab-
sorption cell rapidly to equilibrium by cycling the gas through the
system. Sodium dithionite (200 μM) was added either immediately
prior to CORM-3 or at time intervals after CORM addition. For detecting
CO release in the presence of amino acids, 100 μM CORM-3 was added
to 30mM KPi pH 7.4 containing 200 μM Ala, Asp (sodium salt), Cys
(hydrochloride), His (monohydrochloride), Met or sodium dithionite
(maximum CO release control). In Mb assays, CO release from CORM-3
exploited conversion of reduced myoglobin (red-Mb) to carbonmonoxy-
myoglobin (CO-Mb) in vitro [20,25] (Fig. S1a).
2.3. 1H NMR
1H NMR experiments were conducted in 30mM KPi buﬀer prepared
in distilled H2O at pH 7.4 then freeze-dried and re-dissolved in deut-
erated water (D2O) prior to experiments. For assessment of CORM-3
structural changes that occur upon dissolution in H2O or KPi buﬀer,
CORM-3 stocks were prepared either in H2O (+ 10% (v/v) D2O) or in
0.4–30mM KPi buﬀer after pH adjustment with NaOH/HCl as required.
For peptide titrations, CORM-3 stocks were prepared in 30mM KPi
buﬀer and pH adjusted to 7.4 – 7.7 with NaOH. Concentrations of
CORM-3 were quantiﬁed by 1H NMR using 100 μM
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Fig. 1. (a) Structure of CORM-3 and (b-c) CORM-3 is an ineﬃcient CO-releasing molecule in commonly used biological media and phosphate buﬀers. (b) Gas-phase
FTIR spectrum of CO released from CORM-3 (100 μM) in H2O 30min after the addition of sodium dithionite (200 μM) (black) shown for comparison against a
simulated FTIR spectrum for CO+H2O obtained from HITRAN2012 molecular spectroscopic database (red). (c) Total CO released per mol CORM after addition of
sodium dithionite following 0, 5 or 10min incubation of CORM-3 in 30mM KPi buﬀer pH 7.4 or various bacterial (GDMM, MH-II, LB) or mammalian cell culture
(DMEM or RPMI) media. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
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trimethylsilylpropionate (TSP) as an internal reference, with a 20 s re-
cycle delay for full relaxation between scans. CORM-3 stocks were
stored at 4 °C and typically used within 1–2 h. Synthetic peptides
(Genscript) A3CA3, A3DA3, A3HA3, A3MA3 and A7 had N-terminal
acetylation and C-terminal amidation. Stock solutions of peptides were
prepared in 30mM KPi buﬀer pH 7.4. Peptides with low solubility in
buﬀer were dissolved in d6-DMSO and further diluted with buﬀer. A
maximum of 10% (v/v) d6-DMSO was present during titration experi-
ments. Experiments requiring the presence of DMSO were checked
against controls containing equivalent concentrations of DMSO alone.
Peptide concentrations were determined by 1H NMR relative to the
internal standard TSP (100 μM). Titrations with reduced glutathione
(GSH, Sigma-Aldrich) or oxidised glutathione (GSSG, Sigma-Aldrich)
were conducted as for synthetic peptides. 1H NMR experiments were
carried out on a Bruker Avance-1 800MHz spectrometer using pre-sa-
turation for solvent suppression. Baselines were corrected manually
before spectral signals were integrated using Bruker software. DOSY
experiments were performed as described before [26]. Estimations for
CORM-peptide binding aﬃnities, expressed as the dissociation constant
Kd, were determined as described [27], based either on integrated peak
intensity (slow exchange conditions) or on chemical shift (fast exchange
conditions).
2.4. General bacterial methods
Bacteria used were E. coli K-12 strain MG1655 (F- lambda- ilvG, rfb-
50, rph-1) or the glutathione-deﬁcient mutant strain E. coli MG1655
gshA. Culture growth and viability were determined by standard
methods (see Supplementary information (SI)). MICs were assessed by
exposing 1× 107 cells to serial dilutions of CORM-3 in 96-well mi-
crotiter plates in either glucose deﬁned minimal medium (GDMM) [24]
or MH-II. The MIC was determined as the minimum concentration of
CORM-3 required to inhibit E. coli growth within 16–18 h.
2.5. Eﬀects of media, amino acids or sulfur-containing compounds on
CORM-3 antimicrobial eﬀects
To investigate the eﬀects of media on CORM-3 activity, a CORM-3
solution (10mM) was diluted 10-fold with sterile H2O (as standard),
10 mM PBS, or one of the following growth media: GDMM, LB, MH-II,
DMEM, RPMI-1640. The resulting CORM/media solutions were then
incubated at room temperature for 10min and added to GDMM cultures
(OD595 nm ~ 0.23) at a ﬁnal concentration of 60 μM CORM-3 and 5%
(v/v) media. GDMM was supplemented with 0.25% casamino acids to
determine the eﬀect of a mixture of amino acids. For assessing eﬀects of
individual amino acids (Cys, His, Met, Asp or Ala) or sulfur compounds
(GSH, GSSG, sodium hydrosulﬁde, N-acetyl cysteine (NAC), cystine or
sodium hydrosulﬁde) on CORM-3 antimicrobial activity or Ru accu-
mulation, stocks of 10–40mM CORM-3 were supplemented with a 2-
fold excess of amino acid or the sulfur compounds. The resulting mix-
tures were incubated at room temperature for 10min and added to
bacterial cultures grown in GDMM to give a ﬁnal concentration of
60 μM CORM-3 and 120 μM amino acid/sulfur compound. Growth and
viability of cells was assessed by standard procedures (see SI).
2.6. Measurements of Ru content of whole E. coli cells
The Ru content of E. coli cell pellets was determined by inductively
coupled plasma-atomic emission spectroscopy (ICP-AES) at time inter-
vals after the addition of CORM-3 as described previously [13,16,28]
(see SI).
2.7. RKO clonogenicity measurements of cell survival
Mammalian cell culture experiments were performed using human
colon carcinoma cell line RKO (ATCC CRL-2577) (see SI). Toxicity was
determined by a modiﬁed clonogenic assay [29]. RKO cells, grown to
80–90% conﬂuence, were washed and suspended in PBS to 106 cell
mL−1. Cells were incubated with CORM-3 (0–500 μM) for 1 h at 37 °C
and then transferred to fresh RPMI-1640 medium+ supplements and
grown for 9 days to permit clonal growth. Clonogenicity (i.e. survival
and the subsequent ability to form clones) of RKO cells was determined
by the average number of colonies arising from each CORM-treated cell
suspension, where one colony is representative of one viable cell after
acute exposure to the CORM [29]. The % clonogenicity was determined
by enumerating CORM-treated RKO cells and cells not treated with
CORM. For assessing the eﬀects of media/supplements on CORM-3
cytotoxicity, assays were performed as described above except that cell
suspensions of 5× 105 cells were treated with 25 μM CORM-3 for 1 h in
the presence of PBS, PBS+10% (v/v) FCS (fetal calf serum), PBS+2
mM L-Gln, DMEM or RPMI-1640 growth media. Thus, clonogenicity of
these cells after exposure to CORM-3 was compared to RKO cells
treated in the same medium without CORM-3 (see SI).
2.8. Measurements of Ru content of RKO cells
Conﬂuent RKO cells were resuspended either in 10mM PBS or
DMEM to a ﬁnal concentration of 106 cells mL−1. CORM-3 (50 μM) was
added and the suspensions incubated for 1 h at 37 °C, before cen-
trifugation at 400×g for 5min; the supernatants were discarded. Cells
were washed once in ice-cold PBS, then pellets were digested in nitric
acid and analysed by ICP-AES for Ru content. The level of accumulated
CORM-derived Ru was estimated by the amount of Ru per RKO cell,
assuming 3000 µm3 for the volume of a typical mammalian epithelial
cell [30], assuming a full recovery of 106 cells mL−1 in 10mL prior to
ICP-AES.
3. Results
3.1. CO release from CORM-3 is transient and adversely aﬀected by
biological growth media
The conventional assay for CO release from CORMs is the change in
absorbance of dithionite-reduced myoglobin (Mb) on binding CO [25].
Dithionite is a strong reducing agent and generates a much more
strongly reducing environment than would normally be found inside
cells. In order to test whether the presence of dithionite is critical in CO-
release, we used an alternative assay by measuring CO gas in the
headspace of reaction solutions by gas-phase Fouriertransform Infrared
(FTIR) spectroscopy (Fig. 1b). Adding 100 μM CORM-3 to KPi buﬀer or
various growth media at pH 7 without dithionite gave no detectable CO
release within 30min, consistent with previous observations [25,31]
and only low levels of CO (≤ 1.5 μM) were detected in the headspace
after 10 h (data not shown). However, CO was released upon addition
of 100 μM CORM-3 to KPi buﬀer or various bacterial or mammalian
growth media in a sealed vessel that had been pre-reduced by adding
200 μM sodium dithionite prior to CORM-addition (the 0min condition,
Fig. 1c). The maximum yield of CO obtained was 50 μM, corresponding
to ~ 0.5 mol CO per mol of CORM-3 (Fig. 1c), within the range ob-
served previously for CO capture by red-Mb (0.5–0.7 mol CO per mol of
CORM-3) [25] and conﬁrmed here using the Mb assay and a 10-fold
excess of dithionite (Fig. S1) [25]. Note that previously, no CO-release
was detected by gas chromatography for CORM-3 dissolved in water at
pH 4 or 5.5 over 2 h, but 0.19–0.2 equivalents of CO2 were detected
[32].
CORM-3 prepared in water is relatively stable but in physiological
media, such as Krebs-Henseleit buﬀer, it fails to convert red-Mb to the
CO-Mb adduct, previously attributed to the medium “favoring the re-
lease of CO”, i.e. the CO was released prior to red-Mb addition [20,33].
Incubation of CORM-3 in commonly used bacterial and mammalian
growth media for only 5 or 10min prior to dithionite addition led to a
rapid decline in CO detectable in the headspace by FTIR (Fig. 1c).
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Furthermore, phosphate concentration (4mM and higher) is a key de-
terminant in reducing CO yield from ~ 0.5mol to 0.1 CO per mol of
CORM-3 (Fig. S1b) Thus, after only 10min following addition of
CORM-3 to solutions of standard buﬀers and media, less than 3% of the
total CO ligands are biologically available. Because the antimicrobial
properties of CORM-3 (inhibition of respiration rates or loss of cell
viability) extend over 2–3 h [13,31], and since CO is non-toxic [34], we
conclude that toxicity cannot generally be attributed to CO release.
3.2. CORM-3 undergoes extensive ligand exchange
As CO release from CORM-3 declined rapidly following addition of
the CORM to 30mM KPi buﬀer at pH 7.4, we used 1H NMR to study
structural changes in CORM-3 solutions, speciﬁcally ligand-exchange
reactions. The only 1H signals in CORM-3 are from the glycinate Hα,
which forms a four-line AB quartet, being magnetically non-equivalent
(Fig. 1a). On dissolution of CORM-3 in water, the pH decreases to
around 2.5, and the glycinate protons show the expected AB quartet,
with an additional singlet at 3.69 ppm (Fig. 2a), matching the chemical
shift of free glycine at this pH, suggesting that a signiﬁcant fraction of
the glycine detaches in water (Fig. S2). Upon adjustment of the pH to
7.1 the solution became yellow, which may indicate a further change of
ligand. The 1H NMR spectrum of CORM-3 in H2O at pH 7.1 is altered in
comparison to the spectrum at pH 2.5 (Fig. 2b).
The most intense signal in all spectra corresponds to free glycine, as
indicated by its having an identical chemical shift and identical diﬀu-
sion coeﬃcient to free glycine, as measured by a 2D DOSY (Diﬀusion-
Ordered Spectroscopy) experiment (Fig. 2d). The range of diﬀusion
coeﬃcients (Fig. 2d) indicates that the solution contains at least free
glycine, two monodentate glycinate complexes, and two bidentate
glycinate complexes. Next, the 1H NMR spectrum of CORM-3 in 30mM
KPi buﬀer after the adjustment of the pH to 7.4 was examined (Fig. 2c).
This solution was also yellow. The spectrum resembles that of CORM-3
in H2O at neutral pH but contains additional signals.
Titration with diﬀerent phosphate concentrations (Fig. 2e) demon-
strates changes in the intensities of several bidentate glycinate species,
indicating a complex mixture of species, including displacement of one
or more non-glycine ligands by phosphate. This explains the reduced
CO release in phosphate buﬀer (Fig. 1b and Fig. S1b), and implies that
ligation of phosphate reduces CO release. The complexity of the spectra
in Fig. 2 suggests further ligand exchange reactions, one of which is
presumably the well-characterised WGSR [9,35], in which hydroxide
ions carry out nucleophilic attack on the CO ligand to produce a bound
carboxylate. This would explain the dramatic lowering of pH on
dissolution of CORM-3 in water, and why CO release is reduced sub-
stantially in buﬀer, by concomitant reduction in the number of CO li-
gands, and increased back-donation to any remaining CO ligands.
In summary, the speciation of CORM-3 in KPi buﬀer and neutral pH
is complicated with at least six chemically distinct species, with dif-
ferent CO availabilities. Thus, structural changes generate a mixture of
Ru-carbonyl and Ru-carboxylate species that are no longer able to re-
lease CO upon dithionite addition.
3.3. The toxicity of CORM-3 towards E. coli depends on composition of the
growth media
It is striking that metal-carbonyl CORMs, particularly the Ru-based
compounds, but not the non-metal boranocarbonate CORM-A1, are
eﬀective antimicrobial agents [31]. Since CO gas is tolerated at con-
centrations close to saturation (c. 1 mM) by E. coli [34] and considering
that additional reactants (e.g. a CO acceptor such as Mb or a ligand to
occupy the vacant coordination site on the metal ion) are needed to
promote CO release from CORM-3 and CORM-2, we propose that the
toxicity of Ru-based CORMs is due, not to CO, but to Ru(II) interactions
with cellular components. Indeed, the potency of CORM-3 is abrogated
in the presence of rich growth media: for example, 0.5–100 μM CORM-3
was suﬃcient to kill P. aeruginosa or E. coli cultures in chemically de-
ﬁned growth media [11,13]. In contrast, ~ 400–1500 μM CORM-3 was
required for activity against E. coli, S. aureus, Helicobacter pylori or C.
jejuni cells grown in rich nutrient broths such as LB, Mueller-Hinton
(MH) or Brain-Heart Infusion (BHI) [36–38]. Thus components in rich
growth media may sequester Ru(II) and abrogate its toxic eﬀects, as
demonstrated for other metal ions [39]. This hypothesis was tested by
following the eﬀects of diﬀerent media on CORM-3 toxicity.
E. coli MG1655 cells were grown in minimal medium (GDMM), in
which 60 μM CORM-3 completely inhibits growth and kills bacteria
(Fig. S3). Prior to addition to cultures, CORM-3 stocks were pre-mixed
into water (positive control; Fig. 3a), PBS (Fig. 3a), bacterial growth
media (Fig. 3b), or mammalian cell culture media (Fig. 3c). Pre-mixing
CORM-3 with simple phosphate salt-based media (PBS, GDMM) had no
signiﬁcant eﬀect on CORM-3 toxicity to E. coli (Fig. 3a-b), but pre-
mixing with rich bacterial media (LB or MH-II) (Fig. 3b) or commonly
used mammalian cell culture media (DMEM or RPMI) (Fig. 3c)) com-
pletely abrogated growth inhibition. The ﬁnal concentration of each
medium used was< 5% (v/v) of the total culture volume and was
without signiﬁcant eﬀect on culture growth (not shown). Furthermore,
the Minimal Inhibitory Concentrations (MICs) for CORM-3 against E.
coli were strikingly diﬀerent in simple and rich media, for example,
a)
b)
c)
)e)d
chemical shift (ppm) chemical shift (ppm)δH (ppm)
lo
g 
(d
iff
us
io
n 
r a
te
)(m
2 s
-1
)
Fig. 2. CORM-3 structural changes in
phosphate-containing buﬀers. (a-c) 1H
NMR spectra of CORM-3 (7mM) im-
mediately after dissolution in: (a) un-
buﬀered distilled H2O pH 2.5; (b)
30mM KPi buﬀer and adjustment to
pH 7.4; and (c) adjustment of CORM-3
in H2O to pH 7.1 by addition of NaOH/
HCl. The most intense peak in each
spectrum corresponds to free glycine.
(d) 2D diﬀusion-ordered spectroscopy
(DOSY) spectrum of CORM-3 in KPi
buﬀer pH 7.4. The horizontal axis is 1H
chemical shift (ppm) and the vertical
axis is the diﬀusion rate (log m2 s−1).
The signal at 3.56 ppm corresponds to
free glycine that is no longer bound to
the Ru(II) of CORM-3. The other singlet
signals correspond to the glycinate ligand of CORM-3, monodentate to the Ru(II) ion. The multiplet structure at 3.47 ppm corresponds to an asymmetrical glycine,
most likely bidendate to the Ru(II) ion of CORM-3. (e) Titration of 0.1 mM CORM-3 with increasing concentrations of KPi pH 7.4 (bottom to top) 0.4, 1, 5, 10 and
30mM. The most intense signals arise from free glycine (3.56 ppm) and mixtures of monodentate unsymmetrical glycinate species at 3.44–3.52 ppm and 3.66 –
3.68 ppm that are in reversible equilibria.
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4 μgmL−1 in GDMM but> 512 μgmL−1 in MH-II.
We note that the bacterial growth media that reduce CORM-3
toxicity the most (LB and MH-II; Fig. 3b) are those with least eﬀect on
CO release. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
(Fig. 1b), while media compositions that provide the most eﬀective
antimicrobial activity (GDMM, phosphate buﬀers) have the greatest
reduction in CO release (Fig. 1b), suggesting that the biological eﬀects
of CORM-3 are unrelated to CO release.
Amino acids and peptides are major components of rich biological
growth media but are absent from deﬁned minimal media. To in-
vestigate whether amino acids in rich media are responsible for the
observed protective eﬀects, CORM-3 was added to E. coli cells grown on
GDMM supplemented with 0.25% (w/v) casamino acids (a casein hy-
drolysate); 500 μM CORM-3 was required to elicit the same growth
inhibitory eﬀects as 60 μM CORM-3 in the absence of amino acids
(Fig. 3d). Thus, the amino acid components of rich growth media are
identiﬁed as prime candidates responsible for the alleviation of growth
inhibition by rich media.
3.4. The cellular toxicity of CORM-3 towards cultured mammalian cells is
similarly dependent on composition of the growth media
CORM-3 is reported to be non-toxic to mammalian cells. Clark [20]
reported (but did not show) a lack of toxicity of 10–50 μM CORM-3 to
rat H9c2 cardiac cells cultured in amino acid-rich DMEM, while Seixas
[35] reported IC50 values> 100 μM CORM-3 for RAW264.7 cells, also
in DMEM. Nobre reported minimal toxicity for a range of cultured
eukaryotic cells, again in complex media such as DMEM [36] at up to
500 μM CORM-3. We therefore re-examined, in amino-acid free
medium, CORM-3 cytotoxicity using the human colon carcinoma cell
line RKO (ATCC CRL-2577), selected because the human gastro-
intestinal tract is likely to encounter pathogenic enterobacteria. Acute
exposure to 2.5–50 μM CORM-3 for 1 h in PBS signiﬁcantly decreased
RKO cell clonogenicity relative to untreated control cells (Fig. 4a).
Strikingly, treatment with 50 μM CORM-3 decreased RKO cell clono-
genicity by 86% (p≤ 0.001) and higher concentrations (75–500 μM)
resulted in a total loss of clonogenicity (data not shown).
To identify protective components, RKO survival assays were per-
formed in commonly used growth media or in PBS+ supplements
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Fig. 3. CORM-3 toxicity towards E. coli is alleviated by amino acid components of complex growth media. (a-c) CORM-3 stocks were mixed with a 10-fold excess of:
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(2 mM L-Gln or 10% (w/v) Fetal Calf Serum (FCS)) (Fig. 4b). Treatment
with 25 μM CORM-3 for 1 h in PBS decreased survival relative to un-
treated RKO cells in PBS by 92% (Fig. 4b), compared to only 23% in
RPMI-1640 growth medium (Fig. 4b), whilst in DMEM the survival rate
was enhanced relative to untreated controls (Fig. 4b). Supplementing
PBS with 2mM L-Gln was without eﬀect (Fig. 4b), but PBS with 10% (v/
v) FCS completely alleviated the cytotoxic eﬀects of 25 μM CORM-3
(Fig. 4b). Thus, RPMI-1640, DMEM and/or 10% (v/v) FCS partially or
fully alleviate the acute cytotoxic eﬀects of CORM-3 against human
RKO cells in vitro.
In summary, the eﬀects of CORM-3 on cell growth are similar for
bacterial and mammalian cells: it prevents growth in minimal media,
but has no eﬀect in complex media, due to their amino acid content.
Thus, one of the main reasons for research interest in CORMs – their
potential to kill bacterial but not mammalian cells – requires re-eva-
luation.
3.5. Exogenous Cys/thiols are the main components that alleviate the
antimicrobial activities of CORM-3
To identify the amino acids responsible for protecting cells from
CORM-3-induced toxicity, a growth inhibition screen was conducted:
CORM-3 was mixed with a 2-fold excess of each individual amino acid
for 10min prior to addition to E. coli cultures. Most amino acids failed
to prevent inhibition of growth by 60 μM CORM-3 (e.g. Ala, Fig. 3e, see
Fig. S4 for the full amino acid screen) with three important exceptions.
No inhibition by CORM-3 was observed in the presence of exogenous
Cys, (Fig. 3f) as we reported before [11] and only partial growth in-
hibition was observed in the presence of exogenous His or Met (Fig. 3g,
h). As the addition of these amino acids (120 μM) without CORM had
no signiﬁcant impact on growth (not shown), it is suggested that the
extracellular sequestering of the Ru(II) of CORM by the exogenous
amino acid prevents CORM toxicity. Other sulfur compounds, namely
NAC, cystine (dicysteine), GSH, GSSG and sodium hydrosulﬁde (Fig.
S5), protected E. coli cells from the growth-inhibitory eﬀects of CORM-
3. We previously attributed the eﬀect of NAC to interference with the
interaction of CO with respiratory cytochromes [11], but reactivity
with the thiol now appears more likely.
As well as eﬀects on growth, the bactericidal activity of CORM-3
was similarly aﬀected by the same amino acids or glutathione (Fig. 5a).
Pre-incubation of CORM-3 with a 2-fold excess of Cys, His or GSH re-
stored culture viability to that of the no-reagent control, but Met or
GSSG only partially protected viability (Fig. 5a). Asp or Ala had no
eﬀect (Fig. 5a). The alleviation of CORM-induced growth stasis or
bacterial killing is unrelated to CO loss as no signiﬁcant level of CO into
the headspace of solutions was liberated by any amino acid unless
200 μM sodium dithionite was present (control) (Fig. 5b) and thus,
CORM-3 interactions with selected amino acids do not elicit CO release.
It has been previously reported that GSH/GSSG do not trigger CO re-
lease from CORM-3 [25].
The observation that addition of Cys or GSH to the medium abro-
gates CORM-induced antimicrobial eﬀects immediately suggests that
thiols (–SH) (and to a lesser extent, His, Met and GSSG) act by binding
directly to Ru(II) and sequester it, since thiols are well characterised
metal ligands. We next directly measured the binding of selected amino
acids to CORM-3 using NMR.
3.6. Binding aﬃnities of CORM-3 to selected amino acid residues parallel
antimicrobial eﬀects
Terminally blocked peptides A3XA3 were synthesized, composed of
6 Ala residues (A) with a central amino acid of interest, where X=Ala,
Cys, His, Met or Asp. The only potential interaction with CORM-3 is
expected to be the X sidechain. Peptides were titrated with increasing
amounts of CORM-3 (Fig. 6), and binding interactions were measured
by 1H NMR [27]. Upon titration of A3CA3 with CORM-3, the Cys Hβ
proton signals decreased in intensity (Fig. 6aI). Fitting of the saturation
curve indicated very strong 1:1 binding with a Kd of 5 ± 3 μM
(Fig. 6bI). As more CORM-3 was added, additional signals were ob-
served in the spectrum (Fig. 6aI), indicating slow exchange between
free and bound forms, as expected from the strong aﬃnity. Similarly,
titration of A3HA3 with CORM-3 led to decreased intensities of the
signals corresponding to the His ring, and increases in several new
signals (Fig. 6aII), implying several bound species, as expected from the
complex ligand exchange chemistry described above. Fitting of the
saturation curve gave an estimated Kd of 800 ± 100 μM (Fig. 6bII),
considerably weaker than the aﬃnity of CORM-3 for the Cys-containing
peptide. Titration of A3MA3 with CORM-3 exhibited a shift change and
signal broadening of the Met Hε proton signal (Fig. 6aIII), indicative of
an intermediate exchange rate, with an estimated Kd of ~ 4700 μM
(Fig. 6bIII). Titration of A3DA3 (Fig. 6aIV) or A7 (Fig. S6) elicited no
detectable spectral changes up to 20 or 134 equivalents CORM-3, re-
spectively. Thus, the only detectable binding of amino acid sidechains
to CORM-3 was Cys > > His > Met. These results exactly parallel the
eﬀects of these amino acids on cell growth (Fig. 3) and bactericidal
activity (Fig. 5a), strongly implying that these amino acids in media
reduce the antimicrobial activity of CORM-3 because of their binding to
Ru(II).
In the next section, we present evidence that the antimicrobial ac-
tivity of CORM-3 may be ascribable to its binding of intracellular thiols.
It is therefore relevant to note that the major intracellular thiol, GSH,
behaves as expected, binding strongly to CORM-3 (Fig. 6aV) with an
aﬃnity of 4 ± 2 µM and a 1:1 stoichiometry (Fig. 6bIV), whereas the
oxidised form bound much more weakly (Fig. 6aVI), with an aﬃnity of
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9000 ± 1000 µM (Fig. 6bV)).
3.7. The cytotoxicity of CORM-3 strongly correlates with the intracellular
accumulation of Ru
We have demonstrated that the cytotoxic eﬀects of CORM-3 are
similar for both bacterial and mammalian cells, are not due to CO re-
lease, and are markedly reduced by presence of thiols and amino acids
that bind directly to the Ru(II). To test the hypothesis that this pro-
tection is due to sequestering the Ru(II) extracellularly, we sought to
measure intracellular Ru(II) accumulation by ICP-AES. CORM-3
(15–60 μM) caused a dose-dependent decrease in viability of E. coli cell
cultures relative to untreated controls (Fig. 7a) and a concomitant in-
crease in the intracellular Ru levels after 1 h exposure (Fig. 7b). There
was a strong negative correlation (Fig. 7c) between culture viability and
the corresponding level of intracellular Ru for CORM-3 (p≤ 0.0001).
Thus, the extent of bacterial cell killing by CORM-3 is directly and
strongly associated with the extent of Ru accumulation by E. coli cells.
The level of CORM-derived Ru accumulated by bacteria following
exposure to 60 μM CORM-3 alone was ~ 1.1mM at 20min and
~ 2.1mM at 80min (Fig. 8a). In contrast, pre-incubation of CORM-3
with a 2-fold excess of Cys, His or GSH led to dramatic reductions in Ru
accumulation, particularly for Cys (Fig. 8a). Thus, the alleviation of
CORM-3 antimicrobial eﬀects by exogenous Cys, His or GSH is due to
diminished intracellular Ru accumulation. Pre-incubation of CORM-3
with Asp or Ala had no signiﬁcant eﬀect on intracellular Ru (Fig. 8a),
but Met or GSSG signiﬁcantly lowered the level of cellular Ru accu-
mulation after 20min (Fig. 8a). Therefore, the partial protection of a 2-
fold excess of exogenous Met or GSSG against CORM-3 antimicrobial
eﬀects correlates with diminished accumulation of CORM-derived Ru.
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Fig. 6. Binding aﬃnities of CORM-3 to selected amino acids or glutathione as determined by 1H NMR. (a) 1H NMR spectra of: (I) Cys Hβ of A3CA3 peptide titrated
with 0, 0.17, 0.33, 0.67 and 1.0 equivalents CORM-3; (II) His aromatic proton region of A3HA3 with 0, 0.43, 0.86, 1.4, 2.0, 2.9, 4.2, 5.9, 8.1, 11.5 and 18 equivalents
CORM-3; (III) Met Hε region of A3MA3 with 0, 1, 3, 5, 9, 15, 24, 41, 67 and 134 equivalents CORM-3; (IV) Asp Hβ region of A3DA3 with 0, 0.33, 1.0, 1.5, 3.2, 6.5, 13
and 20 equivalents CORM-3; (V) GSH titrated with 0, 0.25, 0.375, 0.5, 0.625, 0.75, 0.875, 1.0, 1.25, 1.5, 2.0, 2.5 and 5.0 equivalents CORM-3; and (VI) GSSG titrated
with 0, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 15, 18 and 23 equivalents CORM-3. Titrations were performed in 30mM KPi buﬀer, with pH adjusted to ~ 7 – 7.6 where
required. Arrows indicate the direction of signal intensities following increasing addition of CORM-3. (b) Binding curves of the decrease in intensity of 1H NMR
signals in (a) corresponding to: Cys (I), His (II), Met (III), GSH (IV) and GSSG (V) upon increasing additions of CORM-3. 3. The estimated Kd of CORM-3 to each
peptide was determined to be: 5 ± 3 μM for Cys, 800 ± 100 μM for His, 4700 μM for Met, 4 ± 2 μM for GSH and 9190 ± 1000 μM for GSSG.
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The accumulation of CORM-3-derived Ru by human RKO cells followed
the same pattern. The level of accumulated Ru by RKO cells following
1 h exposure to 50 μM CORM-3 was 5.9 ± 2.0mM (Fig. 8b); in the rich
medium DMEM, the level of CORM-3-derived Ru in RKO cells was
signiﬁcantly lower (Fig. 8b).
4. Discussion
CORM-3 is one of the most widely used CORMs in biological and
medical research. Nevertheless, despite early classiﬁcation of the
compound as a ‘fast CO-releasing molecule’ [31], release of CO does not
occur spontaneously in the media used for bacterial or mammalian cell
growth. Indeed, CO was not detected previously in an aqueous solution
of CORM-3 (or CORM-2) using either a CO-speciﬁc electrode or gas
chromatography [31]. The inability of CORM-3 to transfer CO to
deoxyhemoglobin in the absence of reducing agents correlates well with
the absence of CO in the headspace of solutions of CORM-3 and other
[Ru(CO)3Cl2(L)] (L=ligand) complexes [32,35,40]. Many of the bio-
logical eﬀects of CORM-3 appear not to be due to CO liberation
[8,10,16]. The toxic eﬀects of CORM-3 are dramatically alleviated after
pre-equilibration with Cys or GSH, and to a lesser extent His, Met or
GSSG. Earlier, Desmard [11] suggested that inhibition of oxygen con-
sumption by CORM-3 involved Cys residues of the respiratory chain,
but we now demonstrate by NMR a direct interaction of exogenous Cys
and other thiol compounds with the Ru(II) of CORM-3. With hindsight,
a number of prior results have implicated a role of sulfhydryl com-
pounds in attenuating the eﬀects of CORM-3: our previous tran-
scriptomic and respiration studies indirectly implicated sulfur meta-
bolism as a factor in CORM-3 activities [16], and Nobre [41] noted that
E. coli met mutants (defective in Met biosynthesis) showed increased
sensitivity to CORM-2, suggesting that thiol-containing amino acids and
peptides play a protective role.
Furthermore, (i) CO gas is an ineﬀective inhibitor of bacterial
growth [34]; (ii) even a bacterial mutant that lacks all hemes (the
classical biological target of CO) is sensitive to CORM-3 and indeed
accumulates more Ru than wild-type cells [42]; (iii) a CORM-3 deri-
vative that displays no CO release is toxic, reactive with sulfur com-
pounds, and elicits complex gene transcription changes [16]; and (iv)
Cys and GSH abolish the CORM-3-induced inhibition of bacterial
membranes [16]. These ﬁndings substantiate the present view that
CORM-3 toxicity is largely independent of CO and abrogated by sulfur
species via reaction with the Ru center.
We note that the intracellular concentration of Ru is far greater than
its extracellular concentration. This implies either an active transport
mechanism, or (more likely) that, after the mixture of Ru complexes
produced by dissolution of CORM-3 in media diﬀuses into cells, such
complexes react with intracellular targets e.g. intracellular thiols. This
would thus reduce the intracellular concentration of unbound Ru
complex and thereby stimulate the inﬂux of more Ru by mass action.
The major intracellular thiol in E. coli, GSH, is present at millimolar
concentrations in bacterial cells [43,44]). We found that the MIC of
CORM-3 against E. coli was lower against a GSH-deﬁcient (gshA) mutant
at 2 μgmL−1 compared to non-mutant cells at 4 μgmL−1. This suggests
other targets for CORM-derived Ru and that intracellular thiols, such as
GSH, may act as a buﬀer to protect Ru(II)-sensitive targets, such as
active-site Cys or His residues on essential enzymes within bacterial
cells. Obviously, in the absence of free Cys, glutathione, Met or His,
CORM-3 can be toxic by combining with these residues in cell
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Fig. 8. (a) Exogenous amino acids and glutathione inﬂu-
ence CORM-derived Ru accumulation in E. coli. The level
of cellular Ru of E. coli cells grown on GDMM was de-
termined by ICP-AES after 20 and 80min incubation with
60 μM CORM-3 alone (black bars) or 60 μM CORM-3 that
had been pre-mixed with a 2-fold excess of Ala, Asp, Cys,
His, Met, GSH or GSSG. Cys, His and GSH signiﬁcantly
reduced cellular Ru accumulation (p≤ 0.0001). Met and
GSSG slowed Ru accumulation with a signiﬁcant reduc-
tion of cellular Ru at 20min (p≤ 0.001) but not at
80min. Asp and Ala had no eﬀect on Ru accumulation. (b)
The level of cellular CORM-derived Ru accumulation by
human RKO cells following 1 h exposure to 50 μM CORM-
3 in either PBS (black bars) or DMEM (grey bars) was
determined by ICP-AES. RKO cells incubated in PBS ac-
cumulated signiﬁcantly higher levels of CORM-derived Ru
than those treated in DMEM (p≤ 0.05). Data represent 3
biological repeats ± SD. Signiﬁcant diﬀerences were as-
sessed via unpaired t-tests.
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components, albeit without release of CO. Indeed, interactions with
puriﬁed proteins in vitro have been reported: reactions of CORM-3 with
hen egg white lysozyme and bovine serum albumin result in the for-
mation of Ru(II)(CO)2 adducts on surface-exposed His residues, elim-
inating all other ligands to the Ru(II) ion [32,45,46]. A later study in-
vestigated the pharmacokinetics of a large panel of CO-releasing
molecules containing Ru and group 6 metals (Cr, Mo, W), including
CORM-3 (‘Complex 1’) [47]. Its IC50 was 63mg/L (210 μM); many re-
lated complexes had lower toxicities. After administration to mice, the
major proportion, assayed as Ru, remained in blood (predominantly
protein-bound) after 10–60min, and subsequent distribution and me-
tabolism appeared slow. Thus, Ru binding to plasma proteins is a major
factor in the pharmacodynamics of CORM-3.
The data presented here have important implications for the po-
tential application of CORM-3 and similar Ru pro-drugs in therapeutic
applications. Comparatively little attention has been paid to the tox-
icological proﬁles of these compounds or to the CO-depleted molecules
in vivo. A number of toxic chemotherapies ascribe their mechanism of
action to Ru, so that CO-depleted, but Ru-containing, CORM-2 or
CORM-3 may also be detrimental to cellular functions [48,49]. A de-
tailed study [50] of the toxicology of CORM-2 and its ‘CO-depleted’
derivative (i-CORM-2) revealed signiﬁcant cellular toxicity expressed as
decreased cell viability, abnormal cytology, increased apoptosis and
necrosis, cell cycle arrest and diminished mitochondrial activity. These
treatment protocols (growth of cells, lactate dehydrogenase assays and
cell adhesion assays) used complex medium formulations (DMEM with
calf serum). Our results predict that, in simpler media, the observed
toxicities would be much higher and in support we note that even
10 nM CORM-2 induces death in HL-1 heart cells [51]. Interestingly,
inhibition of Complex I (NADH dehydrogenase) by CORM-2 or iCORM-
3 was attributed, as here, to the reactivity of the Ru(II) ion [50]. An
earlier study showed that CORM-2 reduced viability of vascular muscle
cells after 24 h at 40, 170 and 210 μM CORM-2 (and higher con-
centrations) [52], but chronic applications are likely to require much
longer contact times with host tissues and cells. However, cardiomyo-
cytes and renal cells are sensitive to 20 μM CORM-2, a concentration
advocated for therapeutic use [53,54].
We conclude that in physiological conditions CORM-3 releases little
CO. Nevertheless, very high concentrations of extracellular CORM-3
(e.g. 100 μM) release suﬃcient CO to access intracellular cytochromes
(but present at< 0.1 μM in cells), even in the absence of dithionite
[17]. Furthermore small increases in CO levels are observed in CORM-
3-treated rodent organs after sacriﬁce [35] Our data suggest only low
levels of CO release in biological conditions and so the numerous stu-
dies that have interpreted CORM-3 experiments as due to CO release
require re-evaluation. Rather, on dissolution in buﬀer or media, CORM-
3 undergoes a series of ligand displacement and modiﬁcation reactions,
to generate species with accessible Ru(II) centers. These species are
transported and accumulated into bacterial and mammalian cells,
where the Ru reacts with cellular components such as glutathione. One
mechanism of cytotoxicity is therefore predicted to be perturbation of
intracellular redox balance, depletion of glutathione-dependent systems
and Ru(II) coordination to metal-sensitive targets as observed for
toxicity of other non-essential metal ions10. Ru also reacts with in-
tracellular Cys, His, and Met free in the cytosol in proteins. Much of the
selective cytotoxicity against bacterial rather than mammalian cells is
due to cysteine and other amino acids in mammalian growth media,
which react with Ru in the media and prevent its intracellular uptake. It
is the previously unappreciated balance between the opposing eﬀects of
toxicity of CORM-3 and its inactivation that has led to confusing, and
even inconsistent, observations and conclusions in earlier studies.
5. Conclusions
Carbon monoxide-releasing molecules (CORMs) are widely used to
deliver physiologically relevant levels of CO experimentally or
therapeutically, but are also investigated as novel antimicrobial agents
and as a contribution to the threats of antimicrobial resistance.
However, the molecular basis of their toxicity is not well understood. In
this study we showed that CORM-3 releases little CO under commonly
used conditions, and that the active antimicrobial agent is Ru(II), which
binds tightly to thiols. This explains why thiol-rich, complex media
protect cells against CORM-3. Cysteine and reduced glutathione bind
Ru(II) extremely tightly and are eﬀective protectants. These results
necessitate a major reappraisal of the biological eﬀects of CORM-3 and
related CORMs.
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